Ronald H Yanagihara, MD
Hematology/Oncology · Aiea
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Pali Momi Medical Center · 90 clinicians in this group
Hospitals listed: Pali Momi Medical Center · Straub Clinic and Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Yanagihara’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G47486 · Current
Licensed to practise in California · since 1982 · expires 2027-07-31 · University of Minnesota Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Pali Momi Medical CenterAiea, HIAcute Care Hospital · Proprietary · Has an emergency departmentPart of Hawaii Pacific Health, which runs 4 hospitalsPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.166, Oct 2024 – Sep 2025
- Straub Clinic and HospitalHonolulu, HIAcute Care Hospital · Proprietary · Has an emergency departmentPart of Hawaii Pacific Health, which runs 4 hospitalsPatients rate it 4 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 16.47 (10.54 to 22.4) · 566 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.492, Oct 2024 – Sep 2025
See every measure and the patient survey for Pali Momi Medical Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.166 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.84 (0 to 1.82) · 823 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.44 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.97 (113.96 to 211.98) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 218 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 415 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 151 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,907 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.33 (0.12 to 0.54) · 3,322 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 3,332 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.79 (0.59 to 4.99) · 834 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.53 (0 to 3.19) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.61 to 3.75) · 741 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.46 (0 to 13.24) · 243 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.89 (1.03 to 8.74) · 219 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.96 (0.48 to 3.43) · 267 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.42 (0 to 1.16) · 2,957 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.924 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.919 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.312 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 219 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 413 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 15.1 · 144 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 40.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.5 · 422 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.7 · 606 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (4.5 to 9.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.5 to 15.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.2 to 16.3) · 578 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.5) · 387 cases | No different | Jan 2024 – Dec 2024 |
What patients said (419 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 59% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Straub Clinic and Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative respiratory failure rateComplications and deaths | 16.47 (10.54 to 22.4) · 566 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.492 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.02 (1.05 to 3) · 795 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.17 (0.85 to 1.48) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 157.42 (109.15 to 205.69) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 234 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 314 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 157 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,463 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.36) · 3,593 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,831 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.2 to 6.48) · 1,181 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0.11 to 3.11) · 520 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.79 (2.28 to 5.3) · 1,005 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.85 (1.27 to 8.42) · 530 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 197 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 1.11) · 3,199 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 52 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.416 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.63 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.359 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.502 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 270 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.2 · 172 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.8 · 261 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.2 · 314 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.2 · 561 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.4 to 7.1) · 256 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.1 (8.2 to 15) · 256 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 63 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 68 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 63 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (11 to 18.8) · 1,140 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 630 cases | No different | Jan 2024 – Dec 2024 |
What patients said (482 patients answered, 31% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$11,992
Medicare paid this office $11,992 for 129 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 55 | $5,922 | $87 |
| Short return visit (20+ min) | 47 | $2,869 | $57 |
| New patient visit (30+ min) | 13 | $1,024 | $79 |
Who their Medicare patients are
129 Original Medicare patients in 2024. Average age 73 · Women 52% · Also on Medicaid 31% · Health risk score 1.84. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 65% · Cancer 60% · Diabetes 32% · Coronary heart disease 26% · COPD 26% · Chronic kidney disease 22% · Atrial fibrillation 20% · Heart failure 17% · Depression 11% · Stroke 10%.
The office billed $43,545, Medicare allowed $15,120 and paid $11,992; for 153 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 129 | 153 | 73 | 1.84 | $43,545 | $11,992 |
| 2023 | 13 | 14 | 75 | 1.35 | $3,637 | $1,134 |
| 2022 | 30 | 31 | 72 | 2.11 | $9,040 | $1,299 |
| 2021 | 141 | 472 | 75 | 1.90 | $99,248 | $39,233 |
| 2020 | 137 | 462 | 75 | 1.92 | $83,889 | $30,340 |
| 2019 | 150 | 432 | 76 | 2.10 | $79,483 | $26,991 |
| 2018 | 184 | 430 | 75 | 1.83 | $76,403 | $26,054 |
| 2017 | 244 | 593 | 74 | 1.64 | $105,101 | $34,511 |
| 2016 | 241 | 628 | 73 | 1.88 | $112,904 | $36,563 |
| 2015 | 226 | 6,236 | 74 | 2.04 | $287,431 | $92,024 |
| 2014 | 435 | 69,891 | 75 | 1.75 | $3,536,729 | $1,264,211 |
| 2013 | 390 | 99,860 | 76 | 1.79 | $5,024,820 | $1,912,218 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 1 service
| Return visit (30+ min) | 14 | $253 | $17 |
2021: 6 services
| Return visit (30+ min) | 34 | $12,966 | $106 |
| Return visit (30+ min) | 43 | $12,720 | $80 |
| Short return visit (20+ min) | 37 | $4,513 | $69 |
| Short return visit (20+ min) | 57 | $4,454 | $49 |
| New patient visit (45+ min) | 15 | $2,134 | $142 |
| New patient visit (45+ min) | 17 | $1,966 | $116 |
2020: 6 services
| Return visit (30+ min) | 44 | $12,030 | $63 |
| Return visit (30+ min) | 19 | $6,472 | $91 |
| New patient visit (45+ min) | 32 | $3,395 | $106 |
| Short return visit (20+ min) | 53 | $3,030 | $38 |
| Short return visit (20+ min) | 27 | $2,915 | $58 |
| New patient visit (45+ min) | 14 | $1,728 | $123 |
2019: 5 services
| Return visit (30+ min) | 53 | $9,506 | $61 |
| Return visit (30+ min) | 21 | $8,029 | $87 |
| Short return visit (20+ min) | 74 | $3,768 | $36 |
| New patient visit (45+ min) | 23 | $2,371 | $103 |
| Short return visit (20+ min) | 24 | $2,103 | $47 |
2018: 6 services
| Return visit (30+ min) | 44 | $7,633 | $58 |
| Short return visit (20+ min) | 98 | $5,268 | $36 |
| Return visit (30+ min) | 21 | $4,535 | $87 |
| New patient visit (45+ min) | 25 | $3,303 | $132 |
| New patient visit (45+ min) | 26 | $2,577 | $99 |
| Short return visit (20+ min) | 27 | $2,006 | $51 |
2017: 6 services
| Return visit (30+ min) | 61 | $10,045 | $59 |
| Short return visit (20+ min) | 121 | $6,700 | $36 |
| Return visit (30+ min) | 20 | $5,368 | $83 |
| New patient visit (45+ min) | 50 | $4,621 | $92 |
| Short return visit (20+ min) | 51 | $3,907 | $49 |
| New patient visit (45+ min) | 23 | $2,778 | $121 |
2016: 7 services
| Return visit (30+ min) | 62 | $10,656 | $58 |
| Short return visit (20+ min) | 123 | $7,123 | $37 |
| New patient visit (45+ min) | 47 | $4,388 | $93 |
| Short return visit (20+ min) | 50 | $3,973 | $52 |
| New patient visit (45+ min) | 32 | $3,831 | $120 |
| Return visit (30+ min) | 16 | $3,628 | $71 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,145 | $82 |
2015: 13 services
| Return visit (30+ min) | 46 | $8,214 | $65 |
| Short return visit (20+ min) | 92 | $5,568 | $40 |
| New patient visit (45+ min) | 39 | $4,022 | $103 |
| Short return visit (20+ min) | 48 | $3,230 | $51 |
| Return visit (30+ min) | 25 | $2,814 | $78 |
| New patient visit (30+ min) | 38 | $2,292 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $1,536 | $140 |
| New patient visit (45+ min) | 12 | $1,481 | $123 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $1,374 | $65 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $862 | $48 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $25 | None |
| Infusion, normal saline solution, 250 cc | 16 | $17 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $13 | None |
2014: 43 services
| Injection, rituximab, 100 mg | 13 | $247,209 | None |
| Injection, pegfilgrastim, 6 mg | 19 | $156,542 | None |
| Return visit (30+ min) | 174 | $54,229 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 53 | $50,380 | $135 |
| Short return visit (20+ min) | 265 | $28,911 | $62 |
| Injection, zoledronic acid, 1 mg | 28 | $28,849 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $21,084 | None |
| Injection, palonosetron hcl, 25 mcg | 30 | $19,985 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $17,819 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 49 | $15,834 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 50 | $13,863 | $70 |
| Infusion into a vein for hydration, each additional hour | 77 | $8,116 | $15 |
| New patient visit (60+ min) | 45 | $7,963 | $177 |
| New patient visit (45+ min) | 51 | $6,981 | $137 |
| Administration of chemotherapy into vein, each additional hour | 35 | $6,720 | $28 |
| Infusion into a vein for hydration, 31-60 minutes | 38 | $6,376 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,151 | $178 |
| Drawing of blood for a medical problem | 12 | $4,832 | $101 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $4,092 | $62 |
| Injection of additional new drug or substance into vein | 34 | $3,818 | $22 |
| Injection of drug or substance under skin or into muscle | 34 | $3,432 | $25 |
| Administration of additional new drug or substance into vein using push technique | 14 | $3,362 | $62 |
| Biopsy of bone marrow | 23 | $3,356 | $146 |
| Injection of drug or substance into vein | 18 | $2,571 | $57 |
| Injection, paclitaxel, 30 mg | 12 | $1,713 | None |
| Return visit (30+ min) | 15 | $1,470 | $64 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $1,181 | $31 |
| Irrigation of implanted venous access drug delivery device | 15 | $1,090 | $22 |
| Short return visit (20+ min) | 22 | $1,040 | $42 |
| Injection, carboplatin, 50 mg | 12 | $1,030 | None |
| New patient visit (30+ min) | 16 | $990 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $938 | $18 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $782 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 51 | $448 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 24 | $283 | $12 |
| Injection, ranitidine hydrochloride, 25 mg | 13 | $179 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $93 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 37 | $67 | None |
| Infusion, normal saline solution, 250 cc | 35 | $65 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 19 | $65 | None |
| 5% dextrose/water (500 ml = 1 unit) | 20 | $56 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $38 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 13 | $14 | None |
2013: 35 services
| Injection, rituximab, 100 mg | 18 | $274,142 | None |
| Injection, pegfilgrastim, 6 mg | 15 | $122,762 | None |
| Administration of chemotherapy into vein, 1 hour or less | 60 | $86,520 | $147 |
| Return visit (30+ min) | 180 | $63,246 | $94 |
| Injection, zoledronic acid (zometa), 1 mg | 25 | $49,180 | None |
| Injection, palonosetron hcl, 25 mcg | 43 | $41,766 | None |
| Short return visit (20+ min) | 283 | $40,633 | $64 |
| Zoldedronic acid 1mg | 24 | $37,116 | $136 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 60 | $28,478 | $32 |
| Injection, oxaliplatin, 0.5 mg | 12 | $27,222 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $17,851 | $73 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $16,865 | None |
| Administration of prolonged chemotherapy into vein | 15 | $16,624 | $147 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $15,529 | None |
| Administration of chemotherapy into vein, each additional hour | 42 | $12,410 | $31 |
| Infusion into a vein for hydration, each additional hour | 87 | $11,413 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $10,904 | $76 |
| New patient visit (45+ min) | 64 | $9,400 | $147 |
| New patient visit (60+ min) | 50 | $9,219 | $184 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,663 | $170 |
| Administration of additional new drug or substance into vein using push technique | 16 | $6,386 | $64 |
| Injection of additional new drug or substance into vein | 50 | $6,232 | $23 |
| Biopsy of bone marrow | 32 | $5,783 | $165 |
| Injection of drug or substance under skin or into muscle | 45 | $5,281 | $26 |
| Injection, irinotecan, 20 mg | 11 | $3,252 | None |
| Irrigation of implanted venous access drug delivery device | 28 | $2,856 | $25 |
| Short return visit | 34 | $1,928 | $42 |
| Injection, paclitaxel, 30 mg | 13 | $1,741 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,478 | $33 |
| Injection, carboplatin, 50 mg | 15 | $1,328 | None |
| Injection, fluorouracil, 500 mg | 15 | $1,242 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $555 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 32 | $404 | $12 |
| Injection, diphenhydramine hcl, up to 50 mg | 48 | $146 | None |
| Injection, ranitidine hydrochloride, 25 mg | 13 | $145 | None |
Medicaid work
$4,575 in 2024
Medicaid paid $4,575 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFF/OP EST MAY X REQ PHY/QHP | 12 | $4,575 |
| 2024 | 12 | 1 | 12 | $4,575 |
| 2021 | 62 | 2 | 15 | $2,301 |
| 2019 | 122 | 1 | 17 | $5,049 |
| 2018 | 186 | 2 | 16 | $7,249 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 46 | $1,877 |
| Short return visit (20+ min) | 16 | $424 |
2019
| Return visit (30+ min) | 122 | $5,049 |
2018
| Return visit (30+ min) | 142 | $6,066 |
| Short return visit (20+ min) | 44 | $1,182 |
Drugs they prescribed that Part D paid
$284,739
Pharmacies billed $284,739 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 84) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
67 generic and 17 brand-name prescriptions · $284,739 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Letrozole | 12 | $114 | $9 |
Year by year
| 2024 | 84 | 37 | 0% (0) | 20% | $284,739 |
| 2023 | 72 | 26 | 17% (12) | None | $82,188 |
| 2022 | 90 | 33 | None | 56% | $633,554 |
| 2021 | 513 | 97 | 7% (34) | 33% | $2,352,558 |
| 2020 | 533 | 98 | 8% (42) | None | $2,369,591 |
| 2019 | 522 | 107 | 11% (59) | 29% | $1,897,963 |
| 2018 | 590 | 129 | 7% (43) | 18% | $1,240,325 |
| 2017 | 735 | 148 | 8% (60) | None | $788,923 |
| 2016 | 748 | 147 | 9% (68) | 20% | $951,881 |
| 2015 | 519 | 140 | 5% (25) | 13% | $349,536 |
| 2014 | 884 | 141 | 16% (138) | 16% | $484,555 |
| 2013 | 900 | 120 | 19% (175) | None | $404,399 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 2 drugs
| Tagrisso | 21 | $326,582 | $15,552 |
| Dexamethasone | 13 | $165 | $13 |
2021: 12 drugs
| Tagrisso | 65 | $1,010,589 | $15,548 |
| Revlimid | 19 | $323,039 | $17,002 |
| Lenvima | 11 | $219,066 | $19,915 |
| Lorbrena | 11 | $207,969 | $18,906 |
| Alecensa | 17 | $186,781 | $10,987 |
| Dexamethasone | 141 | $1,225 | $9 |
| Ondansetron Odt | 44 | $535 | $12 |
| Levothyroxine | 13 | $343 | $26 |
| Hydrocodone-Acetaminophen | 14 | $227 | $16 |
| Oxycodone | 11 | $221 | $20 |
| Prednisone | 13 | $78 | $6 |
| Furosemide | 16 | $37 | $2 |
2020: 11 drugs
| Tagrisso | 77 | $1,260,983 | $16,376 |
| Lenvima | 19 | $373,627 | $19,665 |
| Revlimid | 23 | $365,518 | $15,892 |
| Lorbrena | 12 | $216,315 | $18,026 |
| Alecensa | 12 | $98,778 | $8,231 |
| Dexamethasone | 114 | $1,006 | $9 |
| Ondansetron Odt | 48 | $624 | $13 |
| Oxycodone | 20 | $436 | $22 |
| Hydrocodone-Acetaminophen | 14 | $351 | $25 |
| Letrozole | 19 | $345 | $18 |
| Ondansetron | 13 | $138 | $11 |
2019: 13 drugs
| Tagrisso | 67 | $1,024,900 | $15,297 |
| Ibrance | 22 | $277,361 | $12,607 |
| Lenvima | 13 | $243,182 | $18,706 |
| Exemestane | 12 | $1,478 | $123 |
| Letrozole | 54 | $1,023 | $19 |
| Dexamethasone | 55 | $727 | $13 |
| Morphine Sulfate Er | 13 | $637 | $49 |
| Hydroxyurea | 19 | $616 | $32 |
| Oxycodone | 19 | $430 | $23 |
| Anastrozole | 25 | $398 | $16 |
| Levothyroxine | 11 | $233 | $21 |
| Ondansetron | 24 | $198 | $8 |
| Ondansetron Odt | 13 | $137 | $11 |
2018: 15 drugs
| Ibrance | 40 | $477,311 | $11,933 |
| Lenvima | 11 | $214,198 | $19,473 |
| Xtandi | 17 | $187,002 | $11,000 |
| Tagrisso | 11 | $173,644 | $15,786 |
| Exemestane | 16 | $15,208 | $950 |
| Letrozole | 119 | $2,293 | $19 |
| Tamoxifen Citrate | 19 | $946 | $50 |
| Anastrozole | 44 | $736 | $17 |
| Dexamethasone | 52 | $660 | $13 |
| Hydrocodone-Acetaminophen | 11 | $370 | $34 |
| Hydroxyurea | 14 | $342 | $24 |
| Ondansetron | 26 | $207 | $8 |
| Dicyclomine | 11 | $182 | $17 |
| Ondansetron Odt | 16 | $146 | $9 |
| Lorazepam | 20 | $43 | $2 |
2017: 16 drugs
| Ibrance | 46 | $526,410 | $11,444 |
| Xtandi | 15 | $154,660 | $10,311 |
| Exemestane | 23 | $17,267 | $751 |
| Letrozole | 178 | $5,234 | $29 |
| Anastrozole | 61 | $1,188 | $19 |
| Tamoxifen Citrate | 18 | $954 | $53 |
| Oxycodone | 21 | $626 | $30 |
| Dexamethasone | 49 | $533 | $11 |
| Ondansetron | 40 | $368 | $9 |
| Hydroxyurea | 14 | $348 | $25 |
| Levothyroxine | 13 | $277 | $21 |
| Hydrocodone-Acetaminophen | 17 | $257 | $15 |
| Lorazepam | 45 | $140 | $3 |
| Loperamide | 12 | $139 | $12 |
| Pantoprazole | 11 | $117 | $11 |
| Sertraline | 13 | $83 | $6 |
2016: 19 drugs
| Revlimid | 23 | $216,328 | $9,406 |
| Ibrance | 17 | $180,951 | $10,644 |
| Sutent | 12 | $164,454 | $13,704 |
| Gilotrif | 14 | $104,544 | $7,467 |
| Exemestane | 29 | $18,342 | $632 |
| Letrozole | 141 | $3,693 | $26 |
| Anastrozole | 58 | $1,591 | $27 |
| Tamoxifen Citrate | 18 | $793 | $44 |
| Ondansetron | 27 | $688 | $25 |
| Dexamethasone | 44 | $665 | $15 |
| Hydrocodone-Acetaminophen | 13 | $516 | $40 |
| Oxycodone | 21 | $500 | $24 |
| Morphine Sulfate Er | 13 | $432 | $33 |
| Potassium Chloride | 13 | $384 | $30 |
| Lorazepam | 36 | $148 | $4 |
| Metoprolol | 11 | $119 | $11 |
| Pantoprazole | 13 | $94 | $7 |
| Prednisone | 14 | $89 | $6 |
| Sertraline | 13 | $60 | $5 |
2015: 9 drugs
| Exemestane | 42 | $20,695 | $493 |
| Letrozole | 109 | $2,714 | $25 |
| Anastrozole | 44 | $816 | $19 |
| Tamoxifen Citrate | 15 | $726 | $48 |
| Dexamethasone | 23 | $278 | $12 |
| Ondansetron | 18 | $262 | $15 |
| Prednisone | 12 | $87 | $7 |
| Lorazepam | 22 | $72 | $3 |
| Omeprazole | 11 | $41 | $4 |
2014: 28 drugs
| Xtandi | 18 | $147,026 | $8,168 |
| Exjade | 14 | $52,574 | $3,755 |
| Exemestane | 20 | $5,727 | $286 |
| Oxycontin | 17 | $4,702 | $277 |
| Letrozole | 119 | $2,473 | $21 |
| Hydrocodone-Acetaminophen | 55 | $2,338 | $43 |
| Morphine Sulfate Er | 19 | $2,077 | $109 |
| Oxycodone | 33 | $1,905 | $58 |
| Bicalutamide | 42 | $1,884 | $45 |
| Hydroxyurea | 27 | $1,097 | $41 |
| Venlafaxine | 11 | $759 | $69 |
| Anastrozole | 38 | $749 | $20 |
| Tamoxifen Citrate | 13 | $505 | $39 |
| Levothyroxine | 34 | $430 | $13 |
| Tamsulosin | 23 | $296 | $13 |
| Dexamethasone | 20 | $222 | $11 |
| Zolpidem | 24 | $178 | $7 |
| Gabapentin | 19 | $126 | $7 |
| Prednisone | 15 | $102 | $7 |
| Alprazolam | 15 | $89 | $6 |
| Metoclopramide | 19 | $84 | $4 |
| Pantoprazole | 13 | $75 | $6 |
| Omeprazole | 11 | $55 | $5 |
| Lisinopril | 11 | $47 | $4 |
| Citalopram Hbr | 11 | $46 | $4 |
| Furosemide | 13 | $39 | $3 |
| Simvastatin | 11 | $34 | $3 |
| Diltiazem | 11 | $33 | $3 |
2013: 28 drugs
| Xtandi | 20 | $155,639 | $7,782 |
| Revlimid | 13 | $107,201 | $8,246 |
| Letrozole | 114 | $4,056 | $36 |
| Exemestane | 18 | $3,364 | $187 |
| Oxycodone | 47 | $2,497 | $53 |
| Hydrocodone-Acetaminophen | 91 | $2,284 | $25 |
| Bicalutamide | 17 | $1,296 | $76 |
| Venlafaxine | 21 | $1,032 | $49 |
| Anastrozole | 31 | $628 | $20 |
| Lansoprazole | 12 | $564 | $47 |
| Morphine Sulfate Er | 21 | $484 | $23 |
| Tamoxifen Citrate | 20 | $458 | $23 |
| Tamsulosin | 27 | $302 | $11 |
| Dexamethasone | 36 | $289 | $8 |
| Levothyroxine | 28 | $216 | $8 |
| Spironolactone | 13 | $153 | $12 |
| Omeprazole | 15 | $149 | $10 |
| Pantoprazole | 18 | $138 | $8 |
| Venlafaxine Hcl Er | 12 | $137 | $11 |
| Warfarin | 11 | $129 | $12 |
| Prednisone | 22 | $110 | $5 |
| Furosemide | 32 | $107 | $3 |
| Metoclopramide | 18 | $103 | $6 |
| Lisinopril | 13 | $98 | $8 |
| Alprazolam | 15 | $96 | $6 |
| Gabapentin | 12 | $86 | $7 |
| Zolpidem | 12 | $86 | $7 |
| Lorazepam | 16 | $65 | $4 |
Money from drug and device companies
$366 in 2025
| 2025 | 4 | 5 | None | $366 |
| 2024 | 1 | 2 | None | $124 |
| 2023 | 5 | 6 | None | $111 |
| 2022 | 2 | 2 | $200 | $325 |
| 2021 | 8 | 17 | $5,748 | $6,125 |
| 2020 | 5 | 17 | $3,444 | $3,603 |
| 2019 | 4 | 6 | $3,425 | $3,841 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Rybrevant | $172 | 2 payments
|
| Janssen Scientific Affairs | Rybrevant | $102 | 1 payment
|
| Daiichi Sankyo | None | $74 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $18 | 1 payment
|
See all 5 published payments
| Janssen Biotech | Meals · 2025-12-16 | Rybrevant | $146 |
| Daiichi Sankyo | Meals · 2025-12-05 | None | $74 |
| Janssen Biotech | Meals · 2025-11-20 | None | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-12 | Lynparza | $18 |
| Janssen Scientific Affairs | Meals · 2025-09-25 | Rybrevant | $102 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $124
| AstraZeneca Pharmaceuticals LP | Enhertu | $124 | 2 payments
|
2023: $111
| AstraZeneca Pharmaceuticals LP | Enhertu | $28 | 2 payments
|
| Novartis Pharmaceuticals | Lutathera | $25 | 1 payment
|
| Astellas Pharma US | Xtandi | $24 | 1 payment
|
| Eisai | Lenvima | $19 | 1 payment
|
| Exelixis | Cabometyx | $15 | 1 payment
|
2022: $325
| Novocure GmbH | None | $200 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $125 | 1 payment
|
2021: $6,125
| AstraZeneca Pharmaceuticals LP | None | $2,398 | 1 payment
|
| G1 Therapeutics | Cosela | $1,500 | 1 payment
|
| BeiGene | None | $1,350 | 1 payment
|
| EMD Serono | Tepmetko | $500 | 1 payment
|
| Pfizer | Inlyta | $218 | 10 payments
|
| Blueprint Medicines | Gavreto | $131 | 1 payment
|
| Janssen Biotech | None | $18 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $3,603
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $2,147 | 3 payments
|
| Blueprint Medicines | None | $1,306 | 1 payment
|
| Pfizer | Lorbrena | $126 | 11 payments
|
| Janssen Pharmaceuticals | Erleada | $12 | 1 payment
|
| Exelixis | Cabometyx | $12 | 1 payment
|
2019: $3,841
| AstraZeneca Pharmaceuticals LP | Tagrisso | $3,554 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $203 | 2 payments
|
| Exelixis | Cabometyx | $73 | 1 payment
|
| Pfizer | Lorbrena | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ABBVIE INC. · Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (Abbv-399) in Subjects With Previously Treated C-Met+ Non-Small Cell Lung Cancer · 2021 | Their institution | $49,441 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2022 | Their institution | $15,000 |
| AbbVie Inc. · 2020 | Their institution | $12,300 |
| CHIESI USA, INC. · Cusa-081-Hem-01 · 2020 | Their institution | $6,500 |
| CHIESI USA, INC. · Retavase · 2021 | Their institution | $5,950 |
| Genentech, Inc. · Ph III Open Label Stdy Atezo Vs Platinum Pemetrexed Gemcitabine for Pdl1 Chemo Naive Stg IV Nsclc · 2019 | Their institution | $5,136 |
| CHIESI USA, INC. · 2021 | Their institution | $5,091 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 73.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1366478240
- Licence
- CA G47486California G47486: Current · expires 2027-07-31
- Trained
- University of Minnesota Medical School, 1974
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00G474860
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 9360 No Name Uno #130, Gilroy, CA, 95020
- NPI first listed
- 2006-06-23
- NPI last updated
- 2013-07-28
This is when the NPI record was last certified, not a medical board exam.